‡a
Author's Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study
‡a
Author's Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer
‡a
impactofmolecularsubtypingandimmuneinfiltrationonpathologicalresponseandoutcomefollowingneoadjuvantpembrolizumabinmuscleinvasivebladdercancer
‡A
Impact of Molecular Subtyping and Immune Infiltration on Pathological Response and Outcome Following Neoadjuvant Pembrolizumab in Muscle-invasive Bladder Cancer
‡9
1
‡a
canpatientswithmuscleinvasivebladdercancerandfibroblastgrowthfactorreceptor3alterationsstillbeconsideredforneoadjuvantpembrolizumabacomprehensiveassessmentfromtheupdatedresultsofthepure01study
‡A
Can Patients with Muscle-invasive Bladder Cancer and Fibroblast Growth Factor Receptor-3 Alterations Still Be Considered for Neoadjuvant Pembrolizumab? A Comprehensive Assessment from the Updated Results of the PURE-01 Study
‡9
1